EVTA Stock Chart & Stats
€1.54
€0.02(1.28%)
At close: 4:00 PM EDT
€1.54
€0.02(1.28%)
Day’s Range― - ―
52-Week Range€0.98 - €3.54
Previous CloseN/A
Volume0.00
Average Volume (3M)940.00
Market Cap
€500.65M
Enterprise Value€1.01B
Total Cash (Recent Filing)€465.59M
Total Debt (Recent Filing)€475.87M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Nov 05, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding355,819,950
10 Day Avg. Volume506
30 Day Avg. Volume940
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.14
Price to Sales (P/S)1.23
P/FCF Ratio-11.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.56Price Target Upside131.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.69
Revenue Forecast (FY)€594.34M
Bulls Say, Bears Say
Bulls Say
Integrated Drug Discovery PlatformEvotec’s integrated capabilities allow customers to access multiple stages of drug development through one partner, which can deepen relationships and support repeat business. Its automation, data-driven and AI-supported platforms also provide a basis for improving discovery productivity and differentiation over time.
Scientific Leadership StrengtheningThe appointment adds an experienced R&D leader with more than 25 years across pharma, biotech and academia. Her mandate to strengthen data, AI and omics capabilities could sharpen Evotec’s scientific differentiation and support better progression of customer programs toward the clinic.
Biodefense Biologics PositioningAdvancing JST-018 from sequence selection through manufacturing and into a first-in-human trial demonstrates Evotec’s ability to combine discovery, development and continuous biologics manufacturing. U.S. biodefense work can strengthen institutional relationships and create a durable reference for scalable CDMO capabilities.
Bears Say
Revenue And Margin ContractionLower revenue alongside a sharp gross-margin compression indicates that Evotec is not currently converting its platform and services footprint into consistent operating leverage. If the weaker mix or higher cost base persists, earnings recovery will remain dependent on execution rather than durable organic profitability.
Persistent Cash ConsumptionNegative operating and free cash flow mean the business is consuming cash instead of funding its activities internally. Although free-cash-flow losses improved from the prior annual period, the renewed cash burn reduces flexibility and can increase reliance on financing while operations remain unprofitable.
Ongoing Loss-Making OutlookManagement’s reaffirmed outlook still implies a substantial adjusted EBITDA loss despite revenue expectations, confirming that scale has not yet translated into sustainable profitability. Continued losses can constrain reinvestment, weaken financial flexibility and leave the business more exposed to execution challenges.
Evotec AG News
EVTA FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was €0.98 and its highest was €3.54 in the past 12 months.
What is Evotec AG’s market cap?
Evotec AG’s market cap is €500.65M.
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.
How were Evotec AG’s earnings last quarter?
Evotec AG released its earnings results on Aug 13, 2026. The company reported -€0.134 earnings per share for the quarter, missing the consensus estimate of -€0.036 by -€0.098.
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Undervalued.
Does Evotec AG pay dividends?
Evotec AG does not currently pay dividends.
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate is -0.16.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,819,950 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Evotec AG reported an EPS of -€0.134 in its last earnings report, missing expectations of -€0.036. Following the earnings report the stock price went down -7.447%.
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in DE:EVTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evotec AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€3.56 (131.46% Upside)
€3.56 (131.46% Upside)
Blogger Sentiment
Bullish
DE:EVTA Sentiment 67%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.31%
12-Months-Change
Fundamentals
Return on Equity
-26.46%
Trailing 12-Months
Asset Growth
-15.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Evotec AG
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
EVTA Stock 12 Month Forecast
Average Price Target
€3.56
▲(131.46% Upside)
Technical Analysis
Alkermes
―
Dr Reddy's Laboratories
―
Lifecore Biomedical
―
HUTCHMED
―
Alpha Teknova
―